Amanote Research
Register
Sign In
Editorial: Gastrointestinal Safety of COX-2 Selective and Nonselective NSAIDs-the Impact of the PRECISION Trial
Alimentary Pharmacology and Therapeutics
- United Kingdom
doi 10.1111/apt.14642
Full Text
Open PDF
Abstract
Available in
full text
Categories
Hepatology
Pharmacology
Gastroenterology
Date
May 17, 2018
Authors
L. Laine
Publisher
Wiley
Related search
Editorial: Gastrointestinal Safety of COX-2 Selective and Nonselective NSAIDs-the Impact of the PRECISION Trial. Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis
Archives of Internal Medicine
Risk of Gastrointestinal Effects With COX-2 Inhibitors and NSAIDs: How Strong Is the Evidence?
BMJ
Reduction in Cancer Risk by Selective and Nonselective Cyclooxygenase-2 (COX-2) Inhibitors
Journal of Experimental Pharmacology
Molecular Medicine
Pharmacology
All-Cause Mortality of Elderly Australian Veterans Using COX-2 Selective or Non-Selective NSAIDs: A Longitudinal Study
British Journal of Clinical Pharmacology
Pharmacology
Risk of Gastrointestinal Effects With COX-2 Inhibitors and NSAIDs: Study Conclusions Do Not Reflect Findings for Celecoxib
BMJ
COX-1 and COX-2 Products in the Gut: Therapeutic Impact of COX-2 Inhibitors
Gut
Gastroenterology
Molecular Basis of Binding Interactions of NSAIDs and Computer-Aided Drug Design Approaches in the Pursuit of the Development of Cyclooxygenase-2 (COX-2) Selective Inhibitors
Risk of Gastrointestinal Effects With COX-2 Inhibitors and NSAIDs: What Does Evidence From Randomised Trials Show About Celecoxib?
BMJ
